Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

X
Trial Profile

A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Cytarabine/daunorubicin (Primary) ; Decitabine (Primary) ; Fludarabine (Primary) ; Ganetespib (Primary) ; Gemtuzumab ozogamicin (Primary) ; Idarubicin (Primary) ; Quizartinib (Primary) ; Vosaroxin (Primary) ; Granulocyte colony-stimulating factors
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AML-18
  • Most Recent Events

    • 12 Dec 2023 Results from course 2 (n=523 ) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 22 Aug 2023 Results(n=852) published in the Blood, describing association of GO2 with MRD and improved survival in older adults
    • 21 Aug 2023 According to ISRCTN Current Controlled Trials record, recruitment end date was 31 Dec 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top